| 特集名 | 透析患者の肝・胆・脾・膵の病変 | |
|---|---|---|
| 題名 | 肝硬変・肝癌のある透析患者の治療 (1) 保存的治療法 -- TAE,PAI，レーザー，PEIT，ラジオ波など | |
| 発刊年月 | 2002年 06月 | |
| 著者 | 篠原 正裕 | 日鋼記念病院放射線科 |
| 【 要旨 】 | 肝細胞癌の代表的な内科的治療法である肝動脈塞栓術(TAE)，経皮的エタノール注入療法(PEIT)，ラジオ波による焼灼治療(RFA)について治療法の原理，方法，副作用，対象患者の選択基準，治療成績について解説した． 前2者は本邦で開発された治療法で，治療成績に関するPEITの評価は定まっていると考えられるが，TAEに関しての海外の報告は評価の低いものが多く，今後の検討を要する． もっとも新しい治療法であるRFAは根治的治療としての期待が高く，長期成績の報告が待たれる． |
|
| Theme | Disease of Liver, Gallbladder, Spleen, and Pancreas in Dialysis Patients | |
|---|---|---|
| Title | Treatment of dialysis patients associated with liver cirrhosis, HCC -- Non-surgical treatment of HCC (TAE, PEIT, RFA) | |
| Author | Masahiro Shinohara | Department of Radiology, Nikko Memorial Hospital |
| [ Summary ] | The author interpreted the principal factors, including, method of treatment, side effects, indications, effectiveness and survival rate for non-surgical treatment of hepatocellular carcinoma. Treatments considered were transcatheter arterial embolization (TAE), percutaneous ethanol injection therapy (PEIT) and radiofrequency ablation (RFA). The former two treatments were developed mainly in Japan. PEIT appeared to be an effective treatment, in contrast, there are several reports from Western countries that TAE does not prolong the survival of HCC patients. It would seem that further assessment with larger, randomized trials for the efficacy of TAE are necessary. The newest treatment, RFA, is expected to be a curative and most effective treatment for HCC. | |